This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution
While part of the story is an increased ability to diagnose cancers early, thanks to...
While part of the story is an increased ability to diagnose cancers early, thanks to...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.